|Day Low/High||43.55 / 43.98|
|52 Wk Low/High||37.43 / 50.65|
Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.
Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.
Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?
The stock market's impressive start to the year is at risk as the government shutdown enters day three. Meanwhile, a series of healthcare deals captivates Wall Street's attention.
So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.
U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.
France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.
Helped by a relaxed regulatory environment, telco giants could pursue M&A to build and prioritize their own content libraries.
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment...
Some French companies will get a temporary windfall, but others will need to pay more tax.
Tesla and General Motors are among this week's names showing reversal patterns.
The French drugmaker's under pressure diabetes treatments slid less than expected but sales of its growing multiple sclerosis products underwhelmed.
Investors keep an eye on another busy slate of earnings.
Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.
Stocks dig further into the red on Monday, Oct. 30, as investors weigh how a proposed phase-in corporate tax rate cut might impact U.S. companies.
Stocks are mixed on Monday as Mueller's Russia investigation takes its first concrete steps.
Here's what you need to know now for Monday, Oct. 23.
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
The Burlington, Mass.-based pharmaceutical firm on Oct. 6 secured approval from the Food and Drug Administration for its osteoarthritis knee pain treatment Zilretta, a non-opioid medicine.
A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 billion in 2016 sales and houses brands such as Advil, Chaptstick, Centrum and Preparation H, among others.
Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.
Shark Tank's Robert Herjavec on why the Equifax hack is different from others cyber attacks.
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of...
An FDA advisory panel recommends that warnings on cough syrups be extended from young children to everyone under 18.
A small portion of the population is prone to "ultra-metabolize" codeine at rates far in excess of the general population.
The dispute became the center of a drug price firestorm.
Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.